Topical administration of verteporfin (1 μmol/L) to established CME-1 xenografts (n = 6) resulted in a significant reduction of tumor volume compared to the DMSO vehicle-treated control group (Fig. 3E; *P < 0.05), further supporting the idea that aberrant YAP1/TAZ signaling could represent a new target for therapeutic intervention in sarcoma patients. Here, YAP1 is linked to sarcoma.